Pyrotinib
Refractory Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Refractory Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axicabtagene Ciloleucel Lyell Immunopharma, Inc. | Phase 3 | BB |
Olaparib OHSU Knight Cancer Institute | Phase 2 | BB |
Vesanoid Rita Assi | Phase 2 | B |
VEMURAFENIB OHSU Knight Cancer Institute | Phase 2 | B |
cd19/22 cart The First Affiliated Hospital of Soochow University | Phase 2 | B |
View all 16 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →